What Medications Are Used to Treat Preeclampsia?

Preeclampsia has no single cure apart from delivering the baby, but a growing set of medications can prevent it, manage its most dangerous symptoms, and protect both mother and child when it develops. The drugs span every stage of pregnancy and beyond: low-dose aspirin weeks before symptoms appear, intravenous magnesium sulfate to stop seizures, fast-acting blood pressure drugs during a crisis, and long-term cardiovascular monitoring after delivery. Which medications matter and when they are used depends on timing, severity, and individual risk factors in ways that are worth understanding clearly.

Aspirin for Prevention

Low-dose aspirin is the most widely recommended preventive medication for preeclampsia. It works by shifting the balance between two molecules involved in blood clotting: it blocks the production of one that promotes platelet clumping while allowing the levels of another that relaxes blood vessels to stay relatively higher.¹ This matters because preeclampsia involves abnormal placental blood flow, and keeping small blood vessels open appears to lower the chance of the condition developing in the first place.

The catch is that both the dose and the timing of aspirin matter more than many guidelines have historically acknowledged. A review of available evidence found that aspirin taken at doses above 100 mg daily, started before 16 weeks of pregnancy, appears most effective at reducing preeclampsia risk. The doses recommended by many major medical organizations may actually fall short of what works best.² In practice, this means that a woman prescribed 81 mg of aspirin starting at 20 weeks may not be getting the full benefit that a higher dose started earlier could provide. If your provider has identified you as high-risk and prescribes aspirin, the conversation about exactly how much and how early is worth having.

Calcium Supplementation in Low-Intake Populations

Calcium is a less flashy preventive measure, but in specific circumstances it matters. Supplementation during pregnancy reduces the risk of preeclampsia, preterm birth, and related complications in populations where dietary calcium intake is low, defined roughly as settings where at least a quarter of people consume less than 800 mg of calcium per day.³ In wealthier countries where dairy and fortified foods are common, most pregnant women already meet that threshold, so routine calcium supplementation for preeclampsia prevention is less strongly emphasized. But in many parts of sub-Saharan Africa, South Asia, and other low- and middle-income regions, calcium supplementation is a recommended public health intervention.

Magnesium Sulfate for Seizure Prevention

When preeclampsia is severe, the greatest immediate danger is eclampsia, a life-threatening seizure. Magnesium sulfate is the single most important drug for preventing it. A large Cochrane review covering more than 11,000 women found that magnesium sulfate more than halved the risk of eclampsia compared with placebo or no treatment.⁴ Head-to-head, it dramatically outperformed alternatives: in one large trial, ten women assigned to phenytoin had eclamptic seizures, compared with zero in the magnesium sulfate group.⁵

The protective effect holds regardless of how severe the preeclampsia is. A case-control study found strong protection in both mild-to-moderate and severe cases, and the benefit persisted whether seizures would have struck before, during, or after delivery.⁶ There is no real controversy about whether magnesium sulfate works; the debate in clinical circles is more about which patients need it, since the vast majority of women with mild preeclampsia will never seize. The drug requires monitoring because high magnesium levels can suppress reflexes and, in extreme overdose, breathing. Still, it remains the gold standard and has been for decades.

Emergency Blood Pressure Medications

When blood pressure spikes dangerously in severe preeclampsia, three intravenous or oral drugs are the standard options: nifedipine, labetalol, and hydralazine. All three bring blood pressure down effectively after the first few doses.⁷ Their performance profiles differ slightly: a single dose of nifedipine lowered average blood pressure most effectively in one trial, while hydralazine overtook the others when cumulative doses were factored in.⁸ In real-world practice, the choice often depends on what the hospital has in stock, the specific clinical picture, and provider experience.

Nifedipine is a calcium channel blocker given by mouth, which makes it practical in settings without reliable intravenous access. Labetalol is typically given intravenously for rapid effect. Hydralazine has been used the longest but can cause unpredictable drops in blood pressure and is used more cautiously today. None of these drugs cure preeclampsia; they buy time by protecting the mother’s brain and organs from the damaging effects of very high blood pressure while the clinical team decides on delivery timing.

Ongoing Blood Pressure Control During Pregnancy

For women with non-severe pregnancy-related hypertension that does not yet require emergency intervention, several oral medications can be used on a daily basis. A large network meta-analysis found that all commonly prescribed antihypertensives, including labetalol, methyldopa, other beta-blockers, and calcium channel blockers, reduced the risk of blood pressure escalating to severe levels by roughly 30 to 70 percent compared with no treatment. Labetalol stood out in that analysis: it was the only drug associated with lower rates of both preeclampsia and fetal or newborn death when compared to placebo, and it performed better than methyldopa and calcium channel blockers specifically for reducing the development of preeclampsia.⁹

Methyldopa has historically been the default choice in many countries because of its long safety record in pregnancy. It works fine at keeping blood pressure in a safe range, but the evidence suggests it may not be the best option if reducing preeclampsia risk is a goal. Labetalol is increasingly favored, though individual responses to any of these drugs vary, and some women need to try more than one before finding what controls their blood pressure without intolerable side effects like fatigue or dizziness.

Medications That Must Be Avoided

Some of the most commonly used blood pressure drugs outside of pregnancy are dangerous during it. ACE inhibitors and angiotensin receptor blockers, the “-pril” and “-sartan” drugs that millions of adults take for hypertension, can cause serious harm to the developing fetus, including kidney failure, underdeveloped lungs, and abnormal skull bone formation.¹⁰ These drugs should be stopped as soon as pregnancy is confirmed or ideally before conception in women planning to become pregnant. This is one reason preeclampsia management uses a different set of blood pressure medications than what most people encounter in general practice.

Why Drug Doses Often Need Adjusting in Pregnancy

Pregnancy changes the way the body handles nearly every medication, and blood pressure drugs are no exception. Blood volume increases substantially, the liver ramps up certain enzyme pathways, and proteins that bind to drugs in the bloodstream shift in concentration. Small studies have shown that both labetalol and nifedipine are cleared faster during pregnancy, likely because of increases in liver enzyme activity that break these drugs down more quickly.¹¹ The practical consequence is that pregnant women may need higher or more frequent doses to get the same blood pressure control they would outside of pregnancy.¹²

Despite this being well recognized in pharmacology, pregnancy-specific dosing guidelines for most antihypertensive drugs simply do not exist. The studies needed to establish them are difficult to conduct for ethical reasons, so clinicians rely heavily on monitoring blood pressure readings and adjusting doses case by case. If you feel like your medication “stopped working” partway through pregnancy, it may genuinely be less effective at the same dose because your body is now processing it faster.

Corticosteroids for the Baby’s Lungs

When severe preeclampsia develops early in pregnancy, delivering the baby is often necessary well before full term. In these situations, antenatal corticosteroids, usually betamethasone, are given to the mother to accelerate the baby’s lung development. A trial in women with severe preeclampsia between 26 and 34 weeks found that corticosteroid treatment cut the rate of respiratory distress syndrome from about 43 percent in the placebo group to 23 percent in the treated group.¹³ This is not a treatment for preeclampsia itself but rather a way to reduce the harm that early delivery, forced by preeclampsia, causes the newborn.

Low-Molecular-Weight Heparin as an Add-On

For high-risk women without blood clotting disorders, adding low-molecular-weight heparin (LMWH) to aspirin has shown some promise. A meta-analysis found that LMWH reduced the incidence of preeclampsia by about a third in these women, though the benefit was only significant in studies where low-dose aspirin was already being used as the baseline prevention. The combination also reduced the risk of preterm birth and fetal growth restriction, though it did not affect placental abruption rates.¹⁴ LMWH is not standard first-line prevention and involves daily injections, so it tends to be reserved for women with a strong history of severe or early-onset preeclampsia in prior pregnancies.

Using Blood Biomarkers to Guide Treatment Decisions

One of the trickiest parts of managing preeclampsia is figuring out who actually has it versus who has some other cause of high blood pressure or protein in the urine during pregnancy. Blood tests measuring two molecules, one that suppresses new blood vessel formation (sFlt-1) and one that promotes it (PlGF), have become useful clinical tools. When reported as a ratio, these markers relate closely to the onset and severity of preeclampsia. Their standout feature is a very high ability to rule out preeclampsia developing within the next week in women where it is suspected but not confirmed.¹⁵

This matters for medication decisions because it helps clinicians avoid unnecessary interventions. A woman with borderline symptoms and a reassuring biomarker ratio might safely avoid hospitalization and aggressive drug treatment, while an alarming ratio in someone who looks clinically stable could push the team toward earlier magnesium sulfate and corticosteroids. The test is increasingly available in high-resource settings but remains uncommon in lower-income health systems.

Postpartum Pain Relief and Blood Pressure

After delivery, women who had preeclampsia often worry about which pain medications are safe, particularly NSAIDs like ibuprofen. A systematic review and meta-analysis found that postpartum NSAID use in women with hypertensive disorders of pregnancy was not associated with worsening high blood pressure. There was a small increase in the length of hospital stay, less than a quarter of a day on average, which was statistically detectable but not clinically meaningful.¹⁶ This is reassuring, since NSAIDs are effective painkillers and are often preferred over opioids after delivery. Individual monitoring still makes sense, but the blanket avoidance of ibuprofen in postpartum preeclampsia patients does not appear to be supported by the pooled data.

Long-Term Cardiovascular Risk After Preeclampsia

Preeclampsia is not just a pregnancy complication that ends with delivery. Women who have had it face a meaningfully higher risk of chronic hypertension and cardiovascular disease in the years and decades that follow, with the risk being especially elevated in women who experienced preeclampsia in more than one pregnancy.¹⁷ Current guidelines recommend cardiovascular screening and ongoing attention for women with a preeclampsia history.¹⁸

What this means in practical terms is that after the postpartum period ends, the medication conversation does not stop. Some women transition onto long-term blood pressure medications, sometimes the same drugs that were off-limits during pregnancy (like ACE inhibitors) are now appropriate. Regular blood pressure checks, cholesterol screening, and attention to kidney function become part of routine care. Many women are not told this clearly at discharge, and the follow-up gap between obstetric care and primary care remains a recognized problem.

Experimental Treatments on the Horizon

The fact that delivery remains the only definitive treatment for preeclampsia has driven researchers to look for drugs that could treat the underlying disease process rather than just managing symptoms. Several candidates have shown encouraging early results.

Pravastatin, a cholesterol-lowering drug, reduced the secretion of sFlt-1, one of the key molecules driving preeclampsia, from human placental and endothelial cells in laboratory studies. It also improved markers of blood vessel health, reducing the adhesion of immune cells to vessel walls and promoting the growth of new endothelial tissue.¹⁹ Clinical trials in pregnant women are underway but have not yet produced definitive results.

Metformin, widely used for diabetes, showed similar promise in laboratory settings. It reduced the secretion of both sFlt-1 and soluble endoglin from placental tissue and improved features of endothelial dysfunction relevant to preeclampsia.²⁰ Interestingly, combining metformin with esomeprazole, a common heartburn drug, produced additive effects, meaning the two together reduced sFlt-1 more than either alone.²¹ Both drugs have well-established safety profiles in pregnancy for other indications, which makes the path to clinical testing somewhat more straightforward than for an entirely new compound.

Further out on the research timeline, a gene-silencing approach using small RNA molecules has shown the ability to reduce sFlt-1 production directly at the placenta. Injecting specially designed, chemically stabilized RNA molecules into pregnant mice and baboons lowered placental sFlt-1 levels and improved clinical signs of preeclampsia.²² This is still firmly in the preclinical stage, but it represents a fundamentally different strategy: instead of treating the symptoms of preeclampsia, it aims to turn off the molecular machinery that causes them.

Magnesium Sulfate Access as a Global Health Problem

Magnesium sulfate is cheap, effective, and has been standard of care for eclampsia prevention for decades. Yet in many low- and middle-income countries, it is frequently unavailable, especially in rural and lower-level health facilities. A qualitative evidence synthesis found that stock-outs are a persistent barrier, driven by limited local production, a small commercial market, fragmented procurement systems, and the paradox of the drug’s low price: pharmaceutical companies have little financial incentive to produce and distribute it.²³

This gap is one of the starkest inequities in maternal health care. Eclampsia kills tens of thousands of women annually, overwhelmingly in settings where a drug costing pennies per dose could prevent most of those deaths. Facility-level managers sometimes try to bypass official procurement channels when they see the system failing, but that improvisation can further fragment supply chains. The problem is not medical knowledge; it is logistics and economics. Until magnesium sulfate reaches every facility where women deliver babies, the global burden of eclampsia will remain far higher than it needs to be.